drugset / Trial / NCT01540500
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this research study is to evaluate whether administration of a CYP1A2 inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites. The safety and tolerability of tasimelteon will also be assessed throughout the study.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluvoxamine | Unknown | 50 mg | — |
| Subject | tasimelteon | Small molecule | 5.66 mg | — |
Indications
No indication recorded.